Cellular Signaling and Cardiovascular Diseases: From NF-κB to Golgi Dynamics

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Cellular Biochemistry".

Deadline for manuscript submissions: 15 October 2026 | Viewed by 1042

Special Issue Editor


E-Mail Website
Guest Editor
Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA
Interests: cardiovascular and vascular biology; molecular and cell biology; immunology and inflammatory signaling; cancer biology; epigenetics and gene expression

Special Issue Information

Dear Colleagues,

Cardiovascular diseases (CVDs) are a leading cause of morbidity and mortality worldwide and are driven by multifaceted cellular and molecular mechanisms. Vascular cells, particularly endothelial cells (ECs) and vascular smooth muscle cells (VSMCs), play central roles in maintaining vascular integrity and function. The dysregulation of signaling pathways in these cells contributes to inflammation, immune activation, and pathological remodeling characteristics in many CVDs. Among these pathways, NF-κB signaling has been extensively studied for its role in promoting vascular inflammation and immune responses. In parallel, epigenetic regulation and emerging insights into subcellular organelle dynamics—such as Golgi apparatus remodeling—have opened up new avenues for understanding the progression of cardiovascular pathology.

For this Special Issue of Biomolecules, “Cellular Signaling and Cardiovascular Diseases: From NF-κB to Golgi Dynamics”, we invite original research and review articles focusing on the molecular signaling mechanisms that drive CVDs. Topics of interest include NF-κB signaling, EC and VSMC biology, inflammation, immunity, epigenetic mechanisms, cell migration, and the roles of organelles in signal transduction. Submissions that incorporate molecular, cellular, and translational approaches are particularly encouraged.

We look forward to receiving your valuable contributions.

Dr. Tong-You Wei
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiovascular diseases
  • NF-κB signaling
  • vascular cells
  • epigenetic regulation
  • vascular inflammation
  • intercellular crosstalk
  • Golgi dynamics
 

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

54 pages, 2276 KB  
Review
Targeting NF-κB Signaling with Natural Products: A Promising Therapeutic Strategy for Cardiovascular Diseases
by Rui Liu, Wencong Liu, Ling Dong, Shuang Ma and Baojun Xu
Biomolecules 2026, 16(4), 491; https://doi.org/10.3390/biom16040491 - 25 Mar 2026
Viewed by 683
Abstract
Cardiovascular diseases (CVDs) remain the primary cause of human morbidity and mortality in the world. Inflammation, oxidative stress, and vascular remodeling are the key factors that make CVDs worse. The nuclear factor κB (NF-κB) signaling pathway is a major regulator in the progression [...] Read more.
Cardiovascular diseases (CVDs) remain the primary cause of human morbidity and mortality in the world. Inflammation, oxidative stress, and vascular remodeling are the key factors that make CVDs worse. The nuclear factor κB (NF-κB) signaling pathway is a major regulator in the progression of CVDs. NF-κB activates wrongly, induces the secretion of pro-inflammatory cytokines (including TNF-α, IL-6, and IL-1β), and enhances reactive oxygen species (ROS) generation. These accelerate endothelial dysfunction, myocardial damage, and atherosclerotic plaque development. Natural products are structurally diverse, multi-targeted, and low toxicity. They offer a promising way to prevent and treat cardiovascular disease by modulating the NF-κB signaling pathway. This review summarizes the recent studies about using natural products (including flavonoids, terpenoids, alkaloids, polyphenols, and polysaccharides) to treat CVDs through the NF-κB pathway, with a critical analysis of evidence strength according to CVDs indication (atherosclerosis, myocardial ischemia/reperfusion injury, pulmonary arterial hypertension, etc.) and study type (in vitro, in vivo animal, and human clinical research). We detail their molecular mechanisms, such as inhibiting the nuclear translocation of NF-κB p65, downregulating IκB phosphorylation, blocking upstream signaling (e.g., TLR4/MyD88, PI3K/Akt, MAPK), and affecting with other pathways (e.g., Nrf2/HO-1, SIRT1) to reduce inflammation and oxidative stress together. We also detail the effects of these natural products in various CVDs models, including atherosclerosis, hypertension, myocardial ischemia/reperfusion injury, diabetic cardiomyopathy, and pulmonary arterial hypertension, highlighting the characteristics of their treatments. Finally, we discuss the challenges of bringing natural products into the clinic and share some ideas to solve difficulties, with an in-depth critical analysis of the translational bottlenecks (poor bioavailability, unclear structure–activity relationships, incomplete mechanistic elucidation, and lack of large-scale clinical trials) and their underlying causes across different natural product classes. In summary, this review offers new perspectives on developing natural product-based therapies targeting the NF-κB signaling pathway for CVDs. It offers useful references for both preclinical studies and clinical applications. Full article
Show Figures

Figure 1

Back to TopTop